For adults with moderate to severe UC or CD1
Their UC and CD goals are in reach and so are yours with Omvoh
Bowel urgency reduction. Long-term remission regardless of biologic exposure.
Reach your goals with Omvoh - an IL-23p19 antagonist for adults with moderately to severely active UC or CD1
Ulcerative Colitis
Crohn's Disease
Lasting Efficacy2,3Ulcerative Colitis
UC: Clinical remission, endoscopic improvement, and HEMR maintained at 4 years.6,7Crohn's Disease
CD: Clinical remission and endoscopic response maintained at 2 years.3
Consistent Efficacy Regardless of Biologic Experience1Ulcerative Colitis
UC: Clinical remission at Week 52 in overall patients and biologic-experience subgroups (bio-naïve and bio-failure).1Crohn's Disease
CD: Clinical remission at Week 52 in overall patients and biologic-experience subgroups (bio-naïve and bio-failure).1
Improvement in Disruptive Symptoms1,2,4,5Ulcerative Colitis
UC: Bowel urgency improvement as early as Week 2 and sustained through 4 years.6,7Crohn's Disease
CD: Bowel urgency improvement as early as Week 6 and sustained through 2 years.1,3,4,7
DosingUlcerative Colitis
In-label flexible dosing in UC, with extended induction and re-induction.1Crohn's Disease
Indication-optimized, with patients in mind.1
Safety Demonstrated Across Multiple Studies for Two Indications UC and CD1Bio-failure=biologic-failure; bio-naïve=biologic-naïve; CD=Crohn's disease; HEMR=histologic endoscopic mucosal remission; IL=interleukin; UC=ulcerative colitis.
Stay in the Loop with Fresh Updates!
Learn more about how Omvoh can help your UC patients with their most burdensome symptom
The VIVID-1 Study: understanding the long-term effects of Omvoh in active Crohn's disease
Omvoh offers comprehensive management for your patients with Crohn's disease
Long-term remission up to 4 years in patients with moderately to severely active UC with Omvoh
Omvoh offers in-label flexible dosing to help meet your patients' needs
Extended induction with Omvoh increased clinical response to 80.3% at Week 24
Omvoh: sustained 3-year efficacy in Crohn's disease
Omvoh: the first IL-23p19i with 4-year remission data in UC
What's New? Watch Now.
From latest articles to infographics, we've got you covered. Explore what's new and stay in the loop!
Prof. Jimmy Limdi
Prof. Jimmy Limdi Reviews 4years Long-Term Remission With OMVOH
Dr. Alissa Walsh
Dr. Alissa: Patient Case of Moderately to Severely Active UC
Prof. Sebastian Zeissig
Bio-naïve Ulcerative Colitis patient treated with Omvoh
Prof. Marc Ferrante
VIVID-2 — key efficacy data in CD
Prof. Sebastian Zeissig
Patient case — TL Experience
Dr. Tim Raine
ECCO 2024 post-congress
Prof. Vipul Jairath
CD launch burst — mirikizumab vs ustekinumab
1. Omvoh EUSPC FEB 2025.
2. Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, et al. Three-year efficacy and safety of mirikizumab following 152 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study. Inflammatory Bowel Diseases. Published online October 25, 2024; Epub: izae253 (Incl Suppl Mat). Available from: https://doi.org/10.1093/ibd/izae253
3. Barnes EL, Sands BE, D'Haens G, Hisamatsu T, Kelly CR, Lu N, et al. Long-term efficacy and safety of mirikizumab following 104 weeks of continuous treatment for Crohn's disease: VIVID-2 open-label extension study. CCC; February 6–8, 2025.
4. Jairath V, et al. Oral presentation at: ECCO 2024. Abstract OP0550.
5. Data on File. REF-72116. Eli Lilly and Company.
6. Sands BE, et al. Inflamm Bowel Dis. 2025;31(7):1876–1890.
7. Data on file, REF-75768, Eli Lilly and Company.